Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Amarin (NASDAQ: AMRN ) gained FDA approval for its drug Vascepa last summer and this lipid-lowering compound is already available to patients in the U.S. However, the company announced today that it has submitted an sNDA, or supplemental new drug application, to expand the drug's approval to a wider patient population. In this video, Fool health-care analyst Max Macaluso explains what this application means, why wider approval could potentially be a boon for this biotech, and long-term risks that investors can't ignore.
Can Amarin Beat the Odds?
Small biotech companies usually crash and burn when it comes to launching drugs -- but can Amarin prove the doubters wrong with its new lipid-lowering drug? In our new premium research report, The Motley Fool's top biotech analyst offers an in-depth look at this drugmaker's upcoming opportunities, along with reasons to buy and sell this stock today. To find out more -- and receive a full year of free bonus updates as news develops -- simply click here now to claim your copy.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.